Bioequivalence Assessment of Two Formulations of Spironolactone in Chinese Healthy Male Volunteers

Abstract

The bioavailability of a new spironolactone ((7α, 17α)-7-(acetylthio)-17-hydroxy-3-oxopregn-4-ene-21-carboxylic acid γ-lactone, CAS 52-01-7) formulation (test) was compared with a commercially available original formulation (reference) of the drug in 20 Chinese healthy male volunteers, aged between 21 and 27. The trial was designed as an open, randomized, single blind two-sequence, two-period crossover study. Under fasting conditions, each subject received a single oral dose of 100 mg spironolactone as a test or reference formulation with a 7-day washout period between the two formulations. The plasma concentrations of spironolactone and its active metabolite canrenone (CAS 976-71-6) were analyzed by a sensitive liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry (LC-APCI-MS) method. The pharmacokinetic parameters included AUC_0–t, AUC_0–∞, C_max, t_1/2, and T_max. Values of AUC_0–t demonstrate nearly identical bioavailability of spironolactone from the examined formulations. The AUC_0–12 of spironolactone was 148.35 ± 39.5 and 144.39 ± 53.02 ng • h/ml for the test and reference formulation, respectively. The AUC_0–60 of the metabolite canrenone was 1873.36 ± 318.10 and 1911.28 ± 355.60 ng h/ml for test and reference formulation, respectively. The maximum plasma concentration (C_max) of spironolactone was 48.34 ±21.16 ng/ml for the test and 47.40 ± 23.40 ng/ml for the reference product and the C_max of the metabolite was 122.90 ± 27.70 and 123.35 ± 27.29 ng/ml for the test and reference product, respectively. No statistical differences were observed for C_max and the area under the plasma concentration-time curve for both spironolactone and its active metabolite canrenone. 90% confidence limits calculated for C_max and AUC from zero to infinity (AUC_0–∞) of spironolactone and its metabolite were included in the bioequivalence range (80%−125% for AUC). This study shows that the test formulation is bioequivalent to the reference formulation for spironolactone and its main active metabolite canrenone.

Key words

Aldosterone antagonists - Antihypertensives - Canrenone, bioequivalence, pharmacokinetics - CAS 52-01-7 - CAS 976-71-6 - Spironolactone, bioequivalence, metabolite, pharmacokinetics

• References

• 1 Muller J. Spironolactone in the management of congestive cardiac failure: a review. Clin Ther. 1986; 9: 63-
• 2 Rocco VK, Ware AJ. Cirrhotic ascites, pathophysiology, diagnosis, and management. Ann Intern Med. 1986; 105: 573
• 3 Skluth HA, Gums JG. Spironolactone: a re-examination. Drug Intell Clin Pharm. 1990; 24: 52
• 4 Karim A, Hribar J, Aksamit W, Doherty M, Chinn LJ. Spironolactone metabolism in man studies by gaschromatography-mass spectrometry. Drug Metab Dispos. 1975; 3: 467
• 5 Abshagen U, Rennekamp H. Isolation and identification of a sulfur-containing metabolite of spironolactone from human urine. Steroids. 1976; 28: 467
• 6 Karim A, Zagarella J, Hutsell TC, Dooley M. Spironolactone III. Canrenone-maximum and minimum steady state plasma levels. Clin Pharmacol Ther. 1976; 19: 177
• 7 The European Agency for the Evaluation of Medicinal Products Committee Proprietary Medical Pruducts. CPMP Note for Guidance of July 2001, CPMP/EWP/QWP/1401/98; the Investigation of Bioavailability and Bioequivalence.
• 8 Dong H, Xu F, Zhang Z, Tian Y, Chen Y. Simultaneous determination of spironolactone and its active metabolite canrenone in human plasma by HPLC-APCI-MS. J Mass Spectrom. 2006; 41: 477-486
• 9 Gochman N, Gantt CL. A fluorimetric method for the determination of a major spironolactone (Aldactone) metabolite in human plasma. J Pharmacol Exp Ther. 1962; 135: 312
• 10 Sadee W, Dagcioglu M, Riegelman S. Fluorometric microassay for spironolactone and its metabolites biological fluids. J Pharm Sci. 1972; 61: 1126
• 11 Overdiek JW, Hermens WA, Merkus FW. Determination of the serum concentration of spironolactone and its metabolites by high-performance liquid chromatography. J Chromatogr. 1985; 341: 279
• 12 Sherry JH, O’Donnel JP, Colby HD. Separation of spironolactone and its biologically active sulfur-containingmetabolites by highperformance liquid chromatography. J Chromatogr. 1986; 374: 183
• 13 Varin F, Tu TM, Benoit F, Theoret Y. High-performance liquid chromatographic determination of spironolactone and its metabolites in human biological fluids after solid-phase extraction. J Chromatogr. 1992; 574: 57
• 14 Jankowski A, Skorek-Jankowska A, Lamparczyk H. Simultaneous determination of spironolactone and its metabolites in human plasma. J. Pharm. Biomed. Anal. 1996; 14: 1359
• 15 US Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance for Industry, Bioanalytical Method Validation. 2001.